Sem Butantan-DV, Qdenga e Dengvaxia seguem como opções contra dengue

Regulatory setback for Brazilian domestic vaccine production (Butantan) strengthens market position of foreign pharmaceutical giants (Takeda, Sanofi). Supply limitations of Qdenga underscore dependency on international manufacturers. Reflects broader tension between national vaccine sovereignty and reliance on multinational pharma capacity.

Similar to dengue vaccine rollout challenges in Philippines (2015-2016) with Dengvaxia, where safety concerns and public trust issues complicated immunization campaigns and highlighted regulatory complexities in tropical disease vaccine deployment.

Consumers face reduced vaccine options in public system (SUS) with Butantan-DV suspended; private sector alternatives (Dengvaxia, Qdenga) remain available but at higher cost; delays in dengue prevention for eligible populations, particularly affecting lower-income households reliant on public health system.

Regulatory scrutiny on vaccine safety protocols and adverse event monitoring; potential acceleration of alternative vaccine approvals; government may need to increase procurement of Qdenga and Dengvaxia to compensate for Butantan-DV gap; possible review of domestic vaccine production capacity and quality control standards; investigation outcomes could impact future public-private vaccine partnerships.